膜杰作
Star Staining
分子别名（Synonym）
Envelope protein,Env polyprotein,Envelope glycoprotein,env
表达区间及表达系统（Source）
DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (ENN-D5244) is expressed from human 293 cells (HEK293). It contains AA Met 281 - Ser 677 (Accession # P29990).
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 46.2 kDa. The protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4, 0.5M Arginine with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (Cat. No. ENN-D5244) is more than 85% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (Cat. No. ENN-D5244) at 1 μg/mL (100 μL/well) can bind Human Anti-E(DENV) Antibody EDE2 A11,Human IgG1 | Human Kappa with a linear range of 1-39 ng/mL (QC tested).
Protocol
背景（Background）
Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV). The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein which is essential for viral attachment and fusion (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia). However, the vaccine of envelope protein still needs to be improved to maximize its efficiency on people never infected with DENV before, which requires more research to be conducted on the DENV envelope protein.
